Forum for Science, Industry and Business

New drugs could also be deployed against lung and pancreatic cancers

Lung and pancreatic cancer are collectively referred to as KRAS tumors, as they share the same genetic error. This error means that the KRAS protein, involved in, among other things, cell division, no longer works properly and is always active.

Kathrin Ciecielski and Prof. Hana Algül (right) discuss the results of the study.

Andreas Heddergott / Technische Universität München

As a result, the cells divide out of control, leading to tumor formation. KRAS tumors make up about a third of all tumors in humans. The problem, however, is that the KRAS protein is also active and plays a crucial role in healthy cells, so that simply deactivating it with drugs is not an option.

New weapon against KRAS tumors

Prof. Hana Algül, Mildred Scheel Professor of Tumor Metabolism and Head of Gastrointestinal Oncology at Medizinische Klinik II at University Hospital rechts der Isar, and his team are therefore on the hunt for alternative points of attack.

“It had previously been thought that the KRAS mutation exerted such severe effects that using other avenues of attack would be doomed to failure,” he explains. In their new study, however, the researchers prove that this is not the case.

They show that, contrary to what experts had previously assumed, the regulatory protein SHP2 is a suitable drug target even in KRAS tumors, and that recently developed SHP2 inhibitors are effective against these tumors.

SHP2 protein is essential for tumor growth

One strand of their work involves mice with a defective KRAS protein. When the team additionally removed the SHP2 protein from the mice, they no longer developed tumors. With these results, the research team was able to prove that SHP2 is essential for tumor formation and that SHP2 might also be a key drug target in aggressive KRAS tumors.

The results were confirmed when they used recently developed SHP2 inhibitors in their mouse model. When the mice were given an SHP2 inhibitor, existing tumors grew more slowly and were easier to control.

Combination therapy helps fight resistance

The results could also solve another problem which arises when treating KRAS tumor: they frequently develop drug resistance. The team tested the new drug in combination with MEK inhibitors, a class of drugs which are already used therapeutically.

“These drugs are effective, but many patients quickly develop resistant cancer cells,” explains Katrin Ciecielski, co-author of the paper. The study found that the new SHP2 inhibitors cause resistant cancer cells to revert to being susceptible to the old MEK inhibitors. A combination of these two drugs could therefore offer a new approach for treating drug-resistant tumors, suggests Hana Algül.

“We have shown that, both on its own and in combination with other drugs, this new class of drug may one day be able to help cancer patients. This could be life-extending for many patients,” says Algül. He thus recommends that clinical trials currently underway should now accept patients with aggressive KRAS tumors. He and his team will soon be applying their findings in their own clinical trial.

Publication:
Ruess, D. A., G. J. Heynen, K. J. Ciecielski, J. Ai, A. Berninger, D. Kabacaoglu, K. Görgülü, Z. Dantes, S. M. Wörmann, K. N. Diakopoulos, A. F. Karpathaki, M. Kowalska, E. Kaya-Aksoy, L. Song, E. A. Zeeuw van der Laan, M. P. López-Alberca, M. Nazaré, M. Reichert, D. Saur, M. Erkan, U. T. Hopt, B. Sainz Jr., W. Birchmeier, R. M. Schmid, M. Lesina and H. Algül: Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase, Nature Medicine, 2018, DOI:
https://www.nature.com/articles/s41591-018-0024-8

High resolution images:
https://mediatum.ub.tum.de/1444702

Contact:
Prof. Hana Algül
Universitätsklinikum rechts der Isar der Technischen Universität München
II. Medizinische Klinik
Tel: +49 (0)89 4140 - 4386
hana.alguel@mri.tum.de

More information:

Prof. Hana Algül holds a Deutsche Krebshilfe Mildred Scheel Professorship. Through these professorships, Deutsche Krebshilfe sponsors young, highly-qualified scientists working in the fields of basic oncological research with clinical relevance or in clinical
cancer research.

The first author of the study, Dr. Dietrich Ruess, worked as guest scientist in the laborarory of Prof. Hana Algül. Now he is back at the Medical Center – University of Freiburg (Klinik für Allgemein- und Viszeralchirurgie).

Profile of Prof. Hana Algül
https://www.professoren.tum.de/en/alguel-hana/

Klinik und Poliklinik für Innere Medizin II
https://www.med2.mri.tum.de/en/index.php

Weitere Informationen:

https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/34671/ - This text on the web

Dr. Ulrich Marsch | Technische Universität München

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...